Literature DB >> 3484740

Role of the nucleoside transport function in the transport and salvage of purine nucleobases.

B Aronow, B Ullman.   

Abstract

Genetic deficiencies in the nucleoside transport function markedly altered the abilities of cultured mutant S49 T lymphoblasts to transport, incorporate, and salvage exogenous hypoxanthine. The concentrations of exogenous hypoxanthine required to reverse azaserine toxicity and replenish azaserine-depleted nucleoside triphosphate pools in AE1 cells, a nucleoside transport-deficient clone, were about 10-fold higher than those required for wild type cells. In a similar fashion, guanine could reverse mycophenolic acid toxicity in wild type but not in AE1 cells. Surprisingly, a second nucleoside transport-deficient clone, 80-5D2, which had lost 80-90% of its ability to transport nucleosides, required lower hypoxanthine concentrations than the wild type parent to reverse these azaserine-mediated effects. The addition of submicromolar concentrations of either p-nitrobenzylthioinosine or dipyridamole, two potent inhibitors of nucleoside transport, to wild type cells mimicked the phenotype of the AE1 cells with respect to hypoxanthine. AE1 cells or p-nitrobenzylthioinosine-treated wild type cells could only transport hypoxanthine at 10-25% the rate of untreated wild type cells, whereas 80-5D2 cells could transport hypoxanthine more efficiently. Adenine transport was also diminished in AE1 and FURD-80-3-6 cells, but not to sufficiently low levels to interfere with their ability to salvage adenine to overcome azaserine toxicity. These studies on S49 cells altered in their nucleoside transport capacity provide powerful genetic evidence that purine nucleobases share a common transport function with nucleosides in these mammalian T lymphoblasts.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484740

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Genetic and physiological characterization of Bacillus subtilis mutants resistant to purine analogs.

Authors:  H H Saxild; P Nygaard
Journal:  J Bacteriol       Date:  1987-07       Impact factor: 3.490

2.  Hypoxanthine enters human vascular endothelial cells (ECV 304) via the nitrobenzylthioinosine-insensitive equilibrative nucleoside transporter.

Authors:  N Osses; J D Pearson; D L Yudilevich; S M Jarvis
Journal:  Biochem J       Date:  1996-08-01       Impact factor: 3.857

3.  Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1).

Authors:  Sylvia Y M Yao; Amy M L Ng; Carol E Cass; Stephen A Baldwin; James D Young
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

4.  Expression of the high-affinity purine nucleobase transporter in mutant mouse S49 cells does not require a functional wild-type nucleoside-nucleobase transporter.

Authors:  B Ullman; J Patrick; K McCartan
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

5.  Incomplete nucleoside transport deficiency with increased hypoxanthine transport capability in mutant T-lymphoblastoid cells.

Authors:  B Aronow; P Hollingsworth; J Patrick; B Ullman
Journal:  Mol Cell Biol       Date:  1986-04       Impact factor: 4.272

6.  Expression of a novel high-affinity purine nucleobase transport function in mutant mammalian T lymphoblasts.

Authors:  B Aronow; D Toll; J Patrick; P Hollingsworth; K McCartan; B Ullman
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

7.  Potentiation of some anticancer agents by dipyridamole against drug-sensitive and drug-resistant cancer cell lines.

Authors:  K Asoh; Y Saburi; S Sato; I Nogae; K Kohno; M Kuwano
Journal:  Jpn J Cancer Res       Date:  1989-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.